Sarepta Therapeutics
SRPT
#5240
Rank
A$2.29 B
Marketcap
A$21.72
Share price
2.07%
Change (1 day)
-60.98%
Change (1 year)
Sarepta Therapeutics is an American medical research company dedicated to the discovery and development of precisely effective gene therapeutics for the treatment of rare neuromuscular diseases.

P/S ratio for Sarepta Therapeutics (SRPT)

P/S ratio as of June 2026 (TTM): 0.7276

According to Sarepta Therapeutics 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.40. At the end of 2025 the company had a P/S ratio of 1.02.

P/S ratio history for Sarepta Therapeutics from 2001 to 2025

PS ratio at the end of each year

Year P/S ratio Change
20251.02-83.35%
20246.10-15.9%
20237.26-40.49%
202212.29.13%
202111.2-55.15%
202024.9-2.22%
201925.5-1.12%
201825.810.75%
201723.3-91.58%
2016276-80.34%
2015> 10002193.16%
201461.313.28%
201354.1146.82%
201221.9918.16%
20112.15-73.42%
20108.10-11.73%
20099.17316.41%
20082.20-73.37%
20078.27-99.44%
2006> 10003874.02%
200536.9-81.29%
200419736.42%
2003145-8.87%
2002159-55.81%
2001359

P/S ratio for similar companies or competitors

Company P/S ratio P/S ratio differencediff. Country
Gilead Sciences
GILD
5.28 625.40%๐Ÿ‡บ๐Ÿ‡ธ USA
PTC Therapeutics
PTCT
3.60 394.50%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
1.35 85.38%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
8.82 1,112.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Insmed
INSM
34.8 4,685.55%๐Ÿ‡บ๐Ÿ‡ธ USA
BioCryst Pharmaceuticals
BCRX
2.50 243.18%๐Ÿ‡บ๐Ÿ‡ธ USA
Avidity Biosciences
RNAM
600 82,332.56%๐Ÿ‡บ๐Ÿ‡ธ USA